-106-

PCT/US00/14471

What is claimed is:

WO 00/74687

- A compound comprising 8 to 30 nucleotides connected by covalent linkages, wherein said oligonucleotide has a sequence specifically hybridizable
 with a nucleic acid encoding a B7 protein and said compound modulates the expression of said B7 protein.
 - 2. The compound of claim 1 which is an antisense oligonucleotide.
- 3. The compound of claim 1, wherein at least one of 10 said covalent linkages is a modified covalent linkage.
 - 4. The compound of claim 1, wherein at least one of said nucleotides has a modified sugar moiety.
- 5. The compound of claim 4, wherein said modified sugar moiety is a modification at the 2' position of any nucleotide, the 3' position of the 3' terminal nucleotide or the 5' position of the 5' terminal oligonucleotide.
 - 6. The compound of claim 1, wherein at least one of said nucleotides has a modified nucleobase.
- The compound of claim 1 wherein said
 oligonucleotide comprises at least one lipophilic moiety which enhances the cellular uptake of said oligonucleotide.
 - 8. The compound of claim 1 wherein said B7 protein is human B7-1.
- 9. The compound of claim 8 wherein said sequence 25 comprises SEQ ID NO: 228, 231, 234, 235, 237, 238, 240, 241, 243, 247, 248, 250 or 251.
 - 10. The compound of claim 1 wherein said B7 protein is human B7-2.
- 11. The compound of claim 10 wherein said sequence 30 comprises SEQ ID NO: 256, 257, 259, 263, 267, 269, 270, 271, 272, 273, 274, 275, 278, 280, 282, 283, 284 or 285.

WO 00/74687 PCT/US00/14471

-107-

12. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

- 13. The composition of claim 12 further comprising an anti-inflammatory or immunosuppressive agent.
- 5 14. A composition comprising
 - (a) the compound of claim 8;
 - (b) the compound of claim 10 and
 - (c) a pharmaceutically acceptable carrier.
- 15. The composition of claim 14 further comprising an 10 anti-inflammatory or immunosuppressive agent.
 - 16. A method of modulating the expression of a B7 protein in cells or tissues comprising contacting said cells or tissues with a compound of claim 1.
- 17. The method of claim 16 wherein said cells or 15 tissues are antigen presenting cells.
 - 18. A method of treating an inflammatory or autoimmune disease or condition in an animal comprising administering to said animal a therapeutically effective amount of a compound of claim 1.
- 19. The method of claim 18 wherein said inflammatory or autoimmune disease or condition is psoriasis, rheumatoid arthritis or multiple sclerosis.
- 20. A method of treating an inflammatory or autoimmune disease or condition in an animal comprising25 administering to said animal a therapeutically effective amount of a composition of claim 12.
 - 21. The method of claim 20 wherein said inflammatory or autoimmune disease or condition is psoriasis, rheumatoid arthritis or multiple sclerosis.
- 22. A method of treating an inflammatory or autoimmune disease or condition in an animal comprising administering to said animal a therapeutically effective amount of a composition of claim 14.

WO 00/74687 PCT/US00/14471

-108-

* · · · •

- 23. The method of claim 22 wherein said inflammatory or autoimmune disease or condition is psoriasis, rheumatoid arthritis or multiple sclerosis.
- 24. A method of inhibiting a T cell response in5 antigen-presenting cells comprising contacting antigenpresenting cells with a compound of claim 1.
 - 25. A method of inhibiting allograft rejection in an animal comprising administering to said animal a compound of claim 1.
- 26. A method of inhibiting allograft rejection in an animal comprising administering to an animal an anti-inflammatory or immunosuppressive agent and a compound of claim 1.
- 27. A method of inhibiting allograft rejection in an 15 animal comprising administering to the animal the composition of claim 12.
 - 28. The method of claim 27 further comprising administering to the animal an anti-inflammatory or immunosuppressive agent.
- 29. A method of inhibiting allograft rejection in an animal comprising administering to the animal the composition of claim 14.
- 30. The method of claim 29 further comprising administering to the animal an anti-inflammatory or immunosuppressive agent.